Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy
Nov. 7, 2025
Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.
In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:
How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.
The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.
Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.
CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.
How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.
Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.
Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.
